Cargando…
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
Recipients of chimeric antigen receptor-modified T (CAR-T) cell therapies for B cell malignancies have profound and prolonged immunodeficiencies and are at risk for serious infections, including respiratory virus infections. Vaccination may be important for infection prevention, but there are limite...
Autores principales: | Walti, Carla S, Loes, Andrea N, Shuey, Kiel, Krantz, Elizabeth M, Boonyaratanakornkit, Jim, Keane-Candib, Jacob, Loeffelholz, Tillie, Wolf, Caitlin R, Taylor, Justin J, Gardner, Rebecca A, Green, Damian J, Cowan, Andrew J, Maloney, David G, Turtle, Cameron J, Pergam, Steven A, Chu, Helen Y, Bloom, Jesse D, Hill, Joshua A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549667/ https://www.ncbi.nlm.nih.gov/pubmed/34702753 http://dx.doi.org/10.1136/jitc-2021-003428 |
Ejemplares similares
-
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy
por: Walti, Carla S., et al.
Publicado: (2021) -
Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19(+) malignancy
por: Pennell, Christopher A, et al.
Publicado: (2022) -
Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022) -
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023) -
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)